Rare Sugar Members Release Glucagon-Like Peptide-1 and Suppress Food Intake in Mice

A sweetener that does more than sweeten

Rare sugars are usually talked about as sweeteners. This study treats them as more than that. New data from a mouse model show that D-allulose triggers release of active GLP-1 in the portal vein and cuts short-term food intake. The effect depends on GLP-1 receptor signaling. That is exactly the kind of mechanism food formulators should watch.

Background

Rare sugars occur naturally in very small amounts. They taste sweet but deliver far fewer calories than sucrose. That makes them attractive for reduced-sugar formulations. The interesting question is whether they also do something metabolic. GLP-1 is a hormone that stimulates insulin secretion, slows gastric emptying, and signals satiety. If a sweetener can raise active GLP-1, it stops being just a sweetener. It becomes a functional ingredient.

What the study did

The study, published in Nutrients with DOI 10.3390/nu17071221, used mice given a single oral gavage of D-allulose. Two doses were tested: 1 g/kg and 3 g/kg body weight. The researchers measured active GLP-1 in portal vein plasma, rather than peripheral blood. That matters because the liver extracts a large share of GLP-1 before it reaches systemic circulation. Portal vein sampling gives a truer view of what the gut has just released.

The team also measured food intake in the short term. To confirm GLP-1 drove the effect, they pretreated mice with exendin(9-39), a GLP-1 receptor antagonist.

Key findings

Both doses raised portal active GLP-1 concentrations significantly. D-allulose also suppressed food intake in a dose-dependent manner. When the GLP-1 receptor was blocked, that suppression disappeared. The food-intake effect ran through a defined hormonal pathway.

What stands out: the same sweetener that replaces sugar may also send a satiety signal.

Endpoint	Observed result
Portal active GLP-1 after 1 g/kg D-allulose	Significant increase
Portal active GLP-1 after 3 g/kg D-allulose	Significant increase
Short-term food intake	Dose-dependent suppression
Food intake after GLP-1 receptor blockade	Suppression blocked

What it means for manufacturers

For ingredient buyers, this shifts the value equation. D-allulose already brings sweetness and low calories to the formula. If it also helps regulate food intake, the ingredient can support satiety and glucose management in a way that standard bulk sweeteners cannot.

Keep expectations grounded. This is a mouse study, not human data. But it gives a concrete mechanism to test in humans. The dose route was oral, which is how foods are eaten. The GLP-1 response appeared after a single exposure. That is not a chronic adaptation. It is an acute physiological event.

The practical opportunity is in products aimed at weight management, diabetes care, and healthy aging. Beverages, yogurts, protein bars, and confections are all candidates. If human trials confirm this pathway, D-allulose could carry a functional story far beyond “no added sugar.”

Do not put a GLP-1 claim on a label yet. Regulatory approval will require human evidence and jurisdiction-specific review. But this study gives developers a reason to plan those trials.

FAQ

Is D-allulose the only rare sugar that does this? The evidence here focuses on D-allulose. Other rare sugars may behave similarly, but this paper does not confirm that.

What doses were used? Mice received 1 g/kg and 3 g/kg D-allulose by oral gavage. Translating those doses to humans requires pharmacokinetic and clinical work. Don’t assume a one-to-one dose.

Does this mean allulose will suppress appetite in people? No. The GLP-1 and feeding responses occurred in mice. Human physiology can differ. The finding is promising and mechanistically clear, but it is not a clinical outcome.

Closing

The science is early. The mechanism is real. D-allulose already works as a low-calorie sweetener. Now it has a documented role in GLP-1 release and food-intake suppression in mice. That makes it one of the more interesting rare sugars on the market. The next step is human research. Ingredient buyers who follow this literature now will be ready when the data land.